Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells
Titel:
Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells
Auteur:
d’Argouges, Sandrine Wissing, Sandra Brandl, Christian Prang, Nadja Lutterbuese, Ralf Kozhich, Alex Suzich, JoAnn Locher, Mathias Kiener, Peter Kufer, Peter Hofmeister, Robert Baeuerle, Patrick A. Bargou, Ralf C.